Erytech Pharma SA Valuation
| ERYPDelisted Stock | USD 0.78 0.04 4.88% |
Erytech Pharma is overvalued. Erytech Pharma SA shows a prevailing Real Value of $0.74 per share. The current price of the firm is $0.78. Our model computes the value of Erytech Pharma SA from reviewing the firm fundamentals such as Profit Margin of (0.03) %, shares outstanding of 34.12 M, and Current Valuation of 211.16 K as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Erytech Pharma's price fluctuation is very steady at this time. Calculation of the real value of Erytech Pharma SA is based on 3 months time horizon. Increasing Erytech Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Erytech Pharma's intrinsic value may or may not be the same as its current market price of 0.78, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.78 | Real 0.74 | Hype 0.78 | Naive 0.87 |
The intrinsic value of Erytech Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Erytech Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Erytech Pharma SA helps investors to forecast how Erytech stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Erytech Pharma more accurately as focusing exclusively on Erytech Pharma's fundamentals will not take into account other important factors: Erytech Pharma Total Value Analysis
Erytech Pharma SA is currently anticipated to have valuation of 211.16 K with market capitalization of 29.57 M, debt of 13.57 M, and cash on hands of 54.05 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Erytech Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
211.16 K | 29.57 M | 13.57 M | 54.05 M |
Erytech Pharma Asset Utilization
One of the ways to look at asset utilization of Erytech is to check how much profit was generated for every dollar of assets it reports. Erytech Pharma SA shows a negative utilization of assets of -0.3 percent, losing $0.003014 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Erytech Pharma SA shows how discouraging it operates for each dollar spent on its assets.Erytech Pharma Ownership Allocation
Erytech Pharma holds a total of 34.12 Million outstanding shares. Roughly 92.35 percent of Erytech Pharma outstanding shares are held by general public with 7.65 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Erytech Pharma Profitability Analysis
Net Loss for the year was (228 K) with profit before overhead, payroll, taxes, and interest of 4.18 M.About Erytech Pharma Valuation
The delisted stock valuation mechanism determines Erytech Pharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Erytech Pharma SA based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Erytech Pharma. We calculate exposure to Erytech Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Erytech Pharma's related companies.ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. The company was incorporated in 2004 and is headquartered in Lyon, France. Erytech Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people.
Erytech Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Erytech Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 31 M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Erytech Stock
If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |